Advances in Surgical Treatment Following Conversion Therapy for Pancreatic Cancer
Abstract
Pancreatic cancer is characterized by an insidious onset, high invasiveness, and poor response to treatment. Radical resection remains the only potentially curative approach currently available. However, approximately 80% of patients are already in the locally advanced or metastatic stage at initial diagnosis and have missed the opportunity for radical surgery. In recent years, with the development of novel drugs and updates to chemotherapy regimens, significant progress has been made in improving the efficacy of conversion therapy. Conversion therapy aims to transform initially unresectable tumors, such as locally advanced or metastatic pancreatic cancer, into a resectable state through systemic therapies (including chemotherapy, targeted therapy, immunotherapy, etc.) combined with localized treatments (such as radiotherapy, interventional therapy, etc.). This approach reduces tumor volume and eliminates micrometastases, thereby improving surgical resection rates and patient survival outcomes. However, considerable controversy remains regarding surgical treatment after conversion therapy for pancreatic cancer. This article provides an overview of conversion therapy regimens and treatment cycles, methods for evaluating therapeutic efficacy post-conversion therapy, the resection rates, and treatment outcomes of surgery following conversion therapy. The key technical points of post-conversion therapy surgery, including R0 resection, venous management, arterial resection and reconstruction, and the management of periarterial divestment, are highlighted. The learning curve for arterial resection and reconstruction is also discussed. Additionally, the potential applications of minimally invasive techniques (such as laparoscopy and robotics) are highlighted. The integration of biomarkers, imaging, and artificial intelligence holds promise for optimizing individualized decision-making. Multidisciplinary collaboration, the comprehensive competence of the surgical team, and the mastery and refinement of surgical skills are also critical factors that influence resectability and therapeutic outcomes after conversion therapy.
Keywords: Pancreatic cancer, Conversion therapy, Conversion surgery, Arterial resection, Periarterial divestment, Review
Full Text:
PDFReferences
SIEGEL R L, GIAQUINTO A N, JEMAL A. Cancer statistics, 2024. CA Cancer J Clin, 2024, 74(1): 12-49. doi: 10.3322/caac.21820.
STOOP T F, JAVED A A, OBA A, et al. Pancreatic cancer. Lancet, 2025, 405(10485): 1182-1202. doi: 10.1016/S0140-6736(25)00261-2.
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263. doi: 10. 3322/caac.21834.
PARK W, CHAWLA A, O'REILLY E M. Pancreatic cancer: a review. JAMA, 2021, 326(9): 851-862. doi: 10.1001/jama.2021.13027.
WU Y, HE S, CAO M, et al. Comparative analysis of cancer statistics in China and the United States in 2024. Chin Med J (Engl), 2024, 137(24): 3093-3100. doi: 10.1097/CM9.0000000000003442.
OBA A, DEL CHIARO M, FUJII T, et al. "Conversion surgery" for locally advanced pancreatic cancer: a position paper by the study group at the joint meeting of the International Association of Pancreatology (IAP) & Japan Pancreas Society (JPS) 2022. Pancreatology, 2023, 23(6): 712-720. doi: 10.1016/j.pan.2023.06.005.
TEMPERO M A, MALAFA M P, Al-HAWARY M, et al. Pancreatic adenocarcinoma, version 2. 2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2021, 19(4): 439-457. doi: 10.6004/jnccn.2021.0017.
Study Group of Pancreatic Surgery in China Society of Surgery of Chinese Medical Association, Pancreatic Disease Committee of China Research Hospital Association. The Guideline for Neoadjuvant Therapy of Pancreatic Cancer in China (2020 Edition). Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 547-558. doi: 10.3969/j.issn. 1674-9081.2020.05.010.
OZAKA M, NAKACHI K, KOBAYASHI S, et al. A randomised phase Ⅱ study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer, 2023, 181: 135-144. doi: 10.1016/j.ejca.2022.12.014.
NICHETTI F, ROTA S, AMBROSINI P, et al. NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis. JAMA Netw Open, 2024, 7(1): e2350756. doi: 10.1001/jamanetworkopen.2023.50756.
DONG L P, LIU Y M, LU W J, et al. Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci, 2022, 26(17): 6316-6327. doi: 10. 26355/eurrev_202209_29656.
WAINBERG Z A, MELISI D, MACARULLA T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet, 2023, 402(10409): 1272-1281. doi: 10. 1016/S0140-6736(23)01366-1.
SU Y Y, CHIANG N J, LI C P, et al. Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: a real-world multicenter study. Front Oncol, 2022, 12: 800842. doi: 10.3389/fonc.2022. 800842.
TULI R, DAVID J, LOBAUGH S, et al. Duration of therapy for locally advanced pancreatic cancer: Does it matter? Cancer Med, 2020, 9(13): 4572-4580. doi: 10.1002/cam4.3081.
TRUTY M J, KENDRICK M L, NAGORNEY D M, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg, 2021, 273(2): 341-349. doi: 10.1097/SLA.000000000 0003284.
WANG Z J, ARIF-TIWARI H, ZAHEER A, et al. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques. Abdom Radiol (NY), 2020, 45(12): 4273-4289. doi: 10.1007/s00261-020-02723-z.
TAKAICHI S, TOMIMARU Y, KOBAYASHI S, et al. Change impact of body composition during neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma undergoing pancreatectomy. Ann Surg Oncol, 2023, 30(4): 2458-2468. doi: 10.1245/s10434-022-12985-0.
NODA Y, PISUCHPEN N, PARAKH A, et al. Does CT overestimate extra-pancreatic perineural invasion in patients with pancreatic ductal adenocarcinoma following neoadjuvant chemoradiation therapy? Br J Radiol, 2024, 97(1155): 607-613. doi: 10.1093/bjr/tqae001.
ALTMAYER S, ARMELIN L M, PEREIRA J S, et al. MRI with DWI improves detection of liver metastasis and selection of surgical candidates with pancreatic cancer: a systematic review and meta-analysis. Eur Radiol, 2024, 34(1): 106-114. doi: 10.1007/s00330-023-10069-5.
SOLOFF E V, Al-HAWARY M M, DESSER T S, et al. Imaging assessment of pancreatic cancer resectability after neoadjuvant therapy: AJR expert panel narrative review. AJR Am J Roentgenol, 2022, 218(4): 570-581. doi: 10.2214/AJR.21.26931.
ABDELRAHMAN A M, GOENKA A H, ALVA-RUIZ R, et al. FDG-PET predicts neoadjuvant therapy response and survival in borderline resectable/locally advanced pancreatic adenocarcinoma. J Natl Compr Canc Netw, 2022, 20(9): 1023-1032.e3. doi: 10.6004/jnccn.2022.7041.
LEE W, OH M, KIM J S, et al. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Br J Surg, 2021, 109(1): 61-70. doi: 10.1093/bjs/znab229.
SEELEN L W F, FLOORTJE Van OOSTEN A, BRADA L J H, et al. Early recurrence after resection of locally advanced pancreatic cancer following induction therapy: an international multicenter study. Ann Surg, 2023, 278(1): 118-126. doi: 10.1097/SLA.0000000000005666.
YE C, SADULA A, REN S, et al. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. Cancer Chemother Pharmacol, 2020, 86(6): 731-740. doi: 10.1007/s00280-020-04165-2.
TSAI S, GEORGE B, WITTMANN D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg, 2020, 271(4): 740-747. doi: 10.1097/SLA. 0000000000003049.
Van MANEN L, GROEN J V, PUTTER H, et al. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. Biomarkers, 2020, 25(2): 186-193. doi: 10.1080/1354750X.2020. 1725786.
OMIYA K, OBA A, INOUE Y, et al. Serum DUPAN-2 could be an alternative biological marker for CA19-9 nonsecretors with pancreatic cancer. Ann Surg, 2023, 277(6): e1278-e1283. doi: 10.1097/SLA. 0000000000005395.
KATO H, KISHIWADA M, HAYASAKI A, et al. Role of serum carcinoma embryonic antigen (CEA) level in localized pancreatic adenocarcinoma: cea level before operation is a significant prognostic indicator in patients with locally advanced pancreatic cancer treated with neoadjuvant therapy followed by surgical resection: a retrospective analysis. Ann Surg, 2022, 275(5): e698-e707. doi: 10.1097/SLA. 0000000000004148.
SPRINGFELD C, FERRONE C R, KATZ M H G, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol, 2023, 20(5): 318-337. doi: 10.1038/s41571-023-00746-1.
WALMA M S, BRADA L J, PATULEIA S I S, et al. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: a multicenter prospective cohort. Eur J Surg Oncol, 2021, 47(3 Pt B): 699-707. doi: 10.1016/j.ejso.2020.11.137.
JANSSEN Q P, Van DAM J L, DOPPENBERG D, et al. FOLFIRINOX as Initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the Trans-Atlantic Pancreatic Surgery Consortium. J Natl Cancer Inst, 2022, 114(5): 695-703. doi: 10.1093/jnci/djac018.
LEE M, KANG J S, KIM H, et al. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. J Hepatobiliary Pancreat Sci, 2023, 30(1): 111-121. doi: 10. 1002/jhbp.1050.
CHEN Z, LV Y, LI H, et al. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer. Medicine (Baltimore), 2021, 100(3): e24068. doi: 10.1097/MD.0000000000024068.
Refbacks
- There are currently no refbacks.



